U.S. FDA approval summary: Nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3484-3488

  Hazarika, Maitreyee ^a   Chuk, Meredith K ^a   Theoret, Marc R ^a   Mushti, Sirisha ^a   He, Kun ^a   Weis, Shawna L ^a   Putman, Alexander H ^a   Helms, Whitney S ^a   Cao, Xianhua ^a   Li, Hongshan ^a   Zhao, Hong ^a   Zhao, Liang ^a   Welch, Joel ^a   Graham, Laurie ^a   Libeg, Meredith ^a   Sridhara, Rajeshwari ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; DACARBAZINE; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ABDUCENS NERVE PARALYSIS; ADOLESCENT; ADRENAL INSUFFICIENCY; ANEMIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CANCER GROWTH; COLITIS; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEMYELINATION; DERMATITIS; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; NAUSEA; NEPHRITIS; NEUROPATHY; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL EDEMA; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNITED STATES; UVEITIS; VITILIGO; ADULT; AGED; ANTAGONISTS AND INHIBITORS; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85019550554     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0712     Document Type: Article

References (8)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. American Cancer Society. Cancer facts & figures 2016. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/index.
3. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
4. Pembrolizumab (Keytruda), Merck & Co., Inc. USPI 09/2014, Drugs@FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf.
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26: 677-704.
6. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu J, Porcelli SA, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A 2010;107:13402-7.
7. Nivolumab (Opdivo), Bristol-Myers Squibb Company. USPI 10/2016, Drugs@FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s016lbl.pdf.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.